OLIARO BOSSO, Simonetta
OLIARO BOSSO, Simonetta
SCIENZA E TECNOLOGIA DEL FARMACO
4-methyl zymosterone and other 4-methyl intermediates of sterol biosynthesis from yeast mutants engineered in the ERG27 gene encoding 3-ketosteroid reductase
2015-01-01 Ferrante, Terenzio; Barge, Alessandro; Albezzano, Claudia; Ballestrazzi Clara; Balliano, Gianni; Oliaro-Bosso, Simonetta
4-Methylzymosterone and Other Intermediates of Sterol Biosynthesis from Yeast Mutants Engineered in the ERG27 Gene Encoding 3-Ketosteroid Reductase
2016-01-01 Ferrante, T; Barge, A; Taramino, S; Oliaro-Bosso, S; Balliano, G
A mutation in yeast oxidosqualene cyclase (Erg7) makes it independent of 3-ketoreductase activity (Erg27)
2012-01-01 Layer Jacob V; Barnes Brett M; Yamasaki Yuji; Barbuch Robert; Li Lingtao; Taramino Silvia; Oliaro-Bosso Simonetta; Balliano Gianni; Bard Martin
A new bevacizumab carrier for intravitreal administration: Focus on stability
2021-01-01 Chirio D.; Peira E.; Sapino S.; Chindamo G.; Oliaro-bosso S.; Adinolfi S.; Dianzani C.; Baratta F.; Gallarate M.
Access of the substrate to the active site of squalene and oxidosqualene cyclases: comparative inhibition, site-directed mutagenesis and homology-modelling studies.
2005-01-01 S. OLIARO-BOSSO; T. SCHULZ-GASCH; S. TARAMINO; M. SCALDAFERRI; F. VIOLA; G. BALLIANO
Access of the substrate to the active site of yeast oxidosqualene cyclase: a modelling and site-directed mutagenesis approach
2009-01-01 S. Oliaro-Bosso; S. Taramino; Y. Ferrari; G. Ermondi; G. Caron; F. Viola; G. Balliano
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis appoach.
2004-01-01 OLIARO-BOSSO S.; SCALDAFERRI M.; TARAMINO S.; F. VIOLA; G. BALLIANO
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach.
2005-01-01 S. OLIARO-BOSSO; T. SCHULZ-GASCH; G. BALLIANO; F. VIOLA.
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach.
2005-01-01 Balliano G.; Oliaro-Bosso S.; Taramino S.; Viola F
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors
2021-01-01 Peraldo-Neia C.; Ostano P.; Mello-Grand M.; Guana F.; Gregnanin I.; Boschi D.; Oliaro-Bosso S.; Pippione A.C.; Carenzo A.; De Cecco L.; Cavalieri S.; Micali A.; Perrone F.; Averono G.; Bagnasacco P.; Dosdegani R.; Masini L.; Krengli M.; Aluffi-Valletti P.; Valente G.; Chiorino G.
Aminopropylindenes derived from Grundmann’s ketone as a novel chemotype of oxidosqualene cyclase inhibitors.
2013-01-01 S. Lange; M. Keller; C. Müller; S. Oliaro-Bosso;G. Balliano; F. Bracher
Analogs of squalene and oxidosqualene inhibit oxidosqualene cyclase of Trypanosoma cruzi expressed in Saccharomyces cerevisiae
2005-01-01 Oliaro Bosso S.; Ceruti M.; Balliano G.; Milla P.; Rocco F.; Viola F.
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention
2017-01-01 Pippione, Agnese C.; Boschi, Donatella; Pors, Klaus; Oliaro-Bosso, Simonetta; Lolli, Marco L.
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3)
2019-01-01 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro Bosso, Marco Lucio Lolli, Donatella Boschi
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3)
2019-01-01 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi
Arylpiperidines as a new class of oxidosqualene cyclase inhibitors
2016-01-01 Keller, M.; Wolfgardt, A.; Müller, C.; Wilcken, R.; Böckler, F.M.; Oliaro-Bosso, S.; Ferrante, T.; Balliano, G.; Bracher, F.
Assessment of in‐situ gelling microemulsion systems upon temperature and dilution condition for corneal delivery of bevacizumab
2021-01-01 Peira E.; Chindamo G.; Chirio D.; Sapino S.; Oliaro-bosso S.; Rebba E.; Ivanchenko P.; Gallarate M.
Cannabinoid Delivery Systems for Pain and Inflammation Treatment
2018-01-01 Bruni, Natascia; Della Pepa, Carlo; Oliaro-Bosso, Simonetta; Pessione, Enrica; Gastaldi, Daniela; Dosio, Franco
Characterization of C-4 demethylation complex of cholesterol biosynthesis
2012-01-01 Brozzu Andrea; Oliaro-Bosso Simonetta; Zonari Daniele; Viola Franca; Poirier Donald; Cunningham David; Herman Gail; Jokela Heili; Poutanen Matti; Balliano Gianni
Characterization of the Channel Constriction Allowingthe Access of the Substrate to the Active Site of YeastOxidosqualene Cyclase
2011-01-01 Simonetta Oliaro-Bosso; Giulia Caron; Silvia Taramino; Giuseppe Ermondi; Franca Viola; Gianni Balliano
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 4-methyl zymosterone and other 4-methyl intermediates of sterol biosynthesis from yeast mutants engineered in the ERG27 gene encoding 3-ketosteroid reductase | 2015 | Ferrante, Terenzio; Barge, Alessandro; Albezzano, Claudia; Ballestrazzi Clara; Balliano, Gianni; Oliaro-Bosso, Simonetta | |
| 4-Methylzymosterone and Other Intermediates of Sterol Biosynthesis from Yeast Mutants Engineered in the ERG27 Gene Encoding 3-Ketosteroid Reductase | 2016 | Ferrante, T; Barge, A; Taramino, S; Oliaro-Bosso, S; Balliano, G | |
| A mutation in yeast oxidosqualene cyclase (Erg7) makes it independent of 3-ketoreductase activity (Erg27) | 2012 | Layer Jacob V; Barnes Brett M; Yamasaki Yuji; Barbuch Robert; Li Lingtao; Taramino Silvia; Oliaro-Bosso Simonetta; Balliano Gianni; Bard Martin | |
| A new bevacizumab carrier for intravitreal administration: Focus on stability | 2021 | Chirio D.; Peira E.; Sapino S.; Chindamo G.; Oliaro-bosso S.; Adinolfi S.; Dianzani C.; Baratta F.; Gallarate M. | |
| Access of the substrate to the active site of squalene and oxidosqualene cyclases: comparative inhibition, site-directed mutagenesis and homology-modelling studies. | 2005 | S. OLIARO-BOSSO; T. SCHULZ-GASCH; S. TARAMINO; M. SCALDAFERRI; F. VIOLA; G. BALLIANO | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: a modelling and site-directed mutagenesis approach | 2009 | S. Oliaro-Bosso; S. Taramino; Y. Ferrari; G. Ermondi; G. Caron; F. Viola; G. Balliano | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis appoach. | 2004 | OLIARO-BOSSO S.; SCALDAFERRI M.; TARAMINO S.; F. VIOLA; G. BALLIANO | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach. | 2005 | S. OLIARO-BOSSO; T. SCHULZ-GASCH; G. BALLIANO; F. VIOLA. | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach. | 2005 | Balliano G.; Oliaro-Bosso S.; Taramino S.; Viola F | |
| AKR1C3 is a biomarker and druggable target for oropharyngeal tumors | 2021 | Peraldo-Neia C.; Ostano P.; Mello-Grand M.; Guana F.; Gregnanin I.; Boschi D.; Oliaro-Bosso S.; Pippione A.C.; Carenzo A.; De Cecco L.; Cavalieri S.; Micali A.; Perrone F.; Averono G.; Bagnasacco P.; Dosdegani R.; Masini L.; Krengli M.; Aluffi-Valletti P.; Valente G.; Chiorino G. | |
| Aminopropylindenes derived from Grundmann’s ketone as a novel chemotype of oxidosqualene cyclase inhibitors. | 2013 | S. Lange; M. Keller; C. Müller; S. Oliaro-Bosso;G. Balliano; F. Bracher | |
| Analogs of squalene and oxidosqualene inhibit oxidosqualene cyclase of Trypanosoma cruzi expressed in Saccharomyces cerevisiae | 2005 | Oliaro Bosso S.; Ceruti M.; Balliano G.; Milla P.; Rocco F.; Viola F. | |
| Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention | 2017 | Pippione, Agnese C.; Boschi, Donatella; Pors, Klaus; Oliaro-Bosso, Simonetta; Lolli, Marco L. | |
| Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) | 2019 | Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) | 2019 | Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Arylpiperidines as a new class of oxidosqualene cyclase inhibitors | 2016 | Keller, M.; Wolfgardt, A.; Müller, C.; Wilcken, R.; Böckler, F.M.; Oliaro-Bosso, S.; Ferrante, T.; Balliano, G.; Bracher, F. | |
| Assessment of in‐situ gelling microemulsion systems upon temperature and dilution condition for corneal delivery of bevacizumab | 2021 | Peira E.; Chindamo G.; Chirio D.; Sapino S.; Oliaro-bosso S.; Rebba E.; Ivanchenko P.; Gallarate M. | |
| Cannabinoid Delivery Systems for Pain and Inflammation Treatment | 2018 | Bruni, Natascia; Della Pepa, Carlo; Oliaro-Bosso, Simonetta; Pessione, Enrica; Gastaldi, Daniela; Dosio, Franco | |
| Characterization of C-4 demethylation complex of cholesterol biosynthesis | 2012 | Brozzu Andrea; Oliaro-Bosso Simonetta; Zonari Daniele; Viola Franca; Poirier Donald; Cunningham David; Herman Gail; Jokela Heili; Poutanen Matti; Balliano Gianni | |
| Characterization of the Channel Constriction Allowingthe Access of the Substrate to the Active Site of YeastOxidosqualene Cyclase | 2011 | Simonetta Oliaro-Bosso; Giulia Caron; Silvia Taramino; Giuseppe Ermondi; Franca Viola; Gianni Balliano |